Company / PP&E (Net)
Protara Therapeutics, Inc. PP&E (Net) History
FY2014-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$372.0K
FY2016
5-year range
$83.0K / $372.0K
FY2014-FY2016
Trend
+66.1%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $83,000 to $372,000 over the past 2 years.
Based on SEC 10-K filings.
$372,000 in FY2016.
Improved from $83,000 to $372,000 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2016, pp&e (net) increased 66.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.74 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2016 | $372.0K | +66.1% |
| FY2015 | $224.0K | +169.9% |
| FY2014 | $83.0K | - |
As of FY2016 · SEC 10-K · Updated Jun 28, 2026